Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q4 2023 Earnings Call Transcript

And I think really demonstrating that, and based on our initial experience at the 12-milligram dose, which only went out to six weeks or so, we feel that patients will be able to reach that high 20%, maybe even low 30% range where the disease becomes transformative. And so it’s really filling out the efficacy side, at least in the first instance on HbF before being able to go back to the agency, and A, to relax some of the inclusion-exclusion criteria in the first instance, and B, to extend the dosing beyond the three months, which is the context of the current trial.

Dae Gon Ha: Excellent. Thank you very much, guys.

Alex Sapir: Yeah. Thanks, Dae Gon.

Operator: Thank you. This concludes the question-and-answer portion of the call. I will now turn the call back over to Fulcrum’s CEO, Alex, for closing remarks. Alex?

Alex Sapir: That’s great. Yeah, thanks so much, Valerie. And I guess, just to wrap up, as you can see from our progress that we’ve made and our plans for 2024, we remain deeply committed to treat the root causes of genetically defined rare diseases and bringing these transformative therapies to patients. And before we conclude today’s call, as I always do, I would like to extend my sincere appreciation and gratitude to my fellow Fulcrum teammates, to the physicians we work with to advance our clinical studies, and finally, and most importantly to the patients and their families. Thanks again to everyone who joined this morning. And please stay safe and healthy. Thanks so much.

Operator: Thank you. Ladies and gentlemen, this does conclude today’s conference. Thank you all for participating. You may now disconnect. Have a great day.